Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

The Lancet HIV

Volumn 2, Issue 4, 2015, Pages e127-e136

  Molina, Jean Michel ^a   Clotet, Bonaventura ^b   van Lunzen, Jan ^c   Lazzarin, Adriano ^d   Cavassini, Matthias ^e   Henry, Keith ^f   Kulagin, Valeriv ^g   Givens, Naomi ^h   de Oliveira, Carlos Fernando ⁱ   Brennan, Clare ^j  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f HENNEPIN COUNTY MEDICAL CENTER   (United States)

^g Clinical Center for Prevention and Control of AIDS   (Russian Federation)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ PPD   (United States)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CREATINE KINASE; CREATININE; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DARUNAVIR; FUSED HETEROCYCLIC RINGS; RITONAVIR;

ABDOMINAL PAIN; ADULT; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CD4+ T LYMPHOCYTE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLATULENCE; GASTROENTERITIS; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SINUSITIS; SYPHILIS; TENDON RUPTURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; VOMITING; ADOLESCENT; ANALYSIS OF VARIANCE; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; DARUNAVIR; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV-1; HUMANS; MALE; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84937911678     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00027-2     Document Type: Article

References (30)

1. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. June, 2013. http://www.who.int/hiv/pub/guidelines/arv2013/en/(accessed Sept 12, 2014).
2. European AIDS Clinical Society Guidelines for treatment of HIVinfected adults in Europe (version 7.1). November, 2014. http://www.eacsociety.org/files/guidelines_english_71_141204.pdf (accessed March 3, 2015).
3. Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA panel. JAMA 2014; 312: 410-25.
4. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November, 2014. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (accessed Sept 9, 2014).
5. Daar ES, Tierney C, Fischl MA, et al, for the AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-56.
6. Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses 2012; 28: 1184-95.
7. Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014; 161: 461-71.
8. DeJesus E, Rockstroh J, Henry K, et al, for the GS-236-0103 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379: 2429-38.
9. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010; 201: 814-22.
10. Schrijvers R, Debyser Z. Quad's in it for antiretroviral therapy? Lancet 2012; 379: 2403-05.
11. ViiV Healthcare. Tivicay: USA prescribing information. ViiV Healthcare: Research Triangle Park, 2013.
12. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012; 56: 1627-29.
13. RaffiF, Rachlis A, Stellbrink HJ, et al, for the SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviralnaive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735-43.
14. RaffiF, Jaeger H, Quiros-Roldan E, et al, for the extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, doubleblind, non-inferiority trial. Lancet Infect Dis 2013; 13: 927-35.
15. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807-18.
16. Walmsley S, Berenguer J, Khuong-Josses M, et al. Dolutegravir regimen statistically superior to efavirenz/tenofovir/emtricitabine: 96-week results from the SINGLE study (ING114467). 21st Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; March 3-6, 2014. Abstract 543.
17. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383: 2222-31.
18. Johnson VA, Calvez V, Gunthard HF, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013; 21: 6-14.
19. EuroQol Research Foundation. What is EQ-5D. 2013. http://www.euroqol.org (accessed Sept 9, 2014).
20. Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res 2001; 10: 517-31.
21. Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health 2006; 9: 320-33.
22. Lennox JL, Dejesus E, Berger DS, et al, for the STARTMRK Investigators. Raltegravir versus efavirenz regimens in treatmentnaive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 39-48.
23. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 1679-88.
24. Janssen Pharmaceuticals. Prezista: USA prescribing information. Titusville: Janssen Pharmaceuticals, 2013.
25. ViiV Healthcare. Triumeq: USA prescribing information. ViiV Healthcare: Research Triangle Park, 2014.
26. Stellbrink HJ, Reynes J, Lazzarin A, et al, for the SPRING-1 Team. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013; 27: 1771-78.
27. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12: 111-18.
28. Burgess E, Blair A, Krichman K, Cutler RE. Inhibition of renal creatinine secretion by cimetidine in humans. Ren Physiol 1982; 5: 27-30.
29. Kastrup J, Petersen P, Bartram R, Hansen JM. The effect of trimethoprim on serum creatinine. Br J Urol 1985; 57: 265-68.
30. KoteffJ, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013; 75: 990-96.